2025
Body mass index and benign prostatic hyperplasia correlate with urinary microbiome diversity and lower urinary tract symptoms in men
Bowie K, Garzotto M, Orwoll E, Karstens L. Body mass index and benign prostatic hyperplasia correlate with urinary microbiome diversity and lower urinary tract symptoms in men. Communications Medicine 2025, 5: 159. PMID: 40328908, PMCID: PMC12056106, DOI: 10.1038/s43856-025-00866-y.Peer-Reviewed Original ResearchLower urinary tract symptomsBenign prostatic hyperplasiaUrinary tract symptomsBody mass indexUrinary microbiomeProstatic hyperplasiaMass indexAssociated with lower urinary tract symptomsLower urinary tractAbsence of infectionCohort of menOsteoporotic fracturesUrinary tractClinical characteristicsSignificant associationBackgroundSeveral studiesUrine samplesHyperplasiaSymptomsStudy designIllumina MiSeqRRNA geneAlpha diversityMenMicrobiome diversityErgonomic Challenges and Considerations in Endoscopic Treatment of Benign Prostatic Hyperplasia
Gardezi M, Sanekommu G, Lee J. Ergonomic Challenges and Considerations in Endoscopic Treatment of Benign Prostatic Hyperplasia. Current Urology Reports 2025, 26: 37. PMID: 40232581, DOI: 10.1007/s11934-025-01266-4.Peer-Reviewed Original ResearchConceptsEndoscopic treatment of benign prostatic hyperplasiaTreatment of benign prostatic hyperplasiaBenign prostatic hyperplasiaProstatic hyperplasiaEndoscopic treatmentModifiable risk factorsReviewThe present reviewEnhance surgical performanceMusculoskeletal painSummaryThe combinationHyperplasiaRisk factorsProlonged proceduresOperating roomSurgeonsSurgeon communitySurgical performancePresent reviewSurgeon educationUrologyErgonomic challengesOptimal ergonomicsErgonomic factorsRising volumeErgonomic considerations
2024
An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia
Cai Y, Jiang H, Li T, Luo D, Li P, Wang Y. An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia. Heliyon 2024, 10: e37906. PMID: 39323819, PMCID: PMC11422042, DOI: 10.1016/j.heliyon.2024.e37906.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstate diseaseProstatic hyperplasiaBurkholderia pseudomallei</i>.Urine culturePulmonary infectionTrimethoprim-sulfamethoxazoleSurvival rate of patientsTreated with imipenemUrinary tract infectionAnti-infective treatmentRate of patientsHistory of hypertensionYear old maleMultiple organ damageProstatic abscessTract infectionsInflammatory markersClinical manifestationsCure rateUnusual caseFatal infectious diseaseOrgan damageDifficulty urinatingSurvival rate
2022
Implementation of an Appointment‐Based Cardiac Rehabilitation Approach: A Single‐Center Experience
Wright CX, Fournier S, Deng Y, Meng C, Hiller S, Oen‐Hsiao J, Dreyer RP. Implementation of an Appointment‐Based Cardiac Rehabilitation Approach: A Single‐Center Experience. Journal Of The American Heart Association 2022, 11: e024066. PMID: 35499969, PMCID: PMC9238587, DOI: 10.1161/jaha.121.024066.Peer-Reviewed Original ResearchConceptsLogistic regression modelsHealth outcomesCR programSex/age subgroupMultivariable logistic regression modelCardiovascular disease populationsDose-response benefitsSingle-center experienceDietary fat intakeBenign prostatic hyperplasiaFinal logistic regression modelLack of exerciseYale New Haven HealthPredictors of completionRegression modelsBlack patientsFat intakeMean ageProstatic hyperplasiaBlack raceCR completionRisk factorsCardiovascular diseaseDisease populationAge subgroups
2021
The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder
Bosse G, Cadeddu R, Floris G, Farero R, Vigato E, Lee S, Zhang T, Gaikwad N, Keefe K, Phillips P, Bortolato M, Peterson R. The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder. Journal Of Clinical Investigation 2021, 131 PMID: 33848264, PMCID: PMC8121512, DOI: 10.1172/jci143990.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid Self-AdministrationDehydroepiandrosterone sulfateSelf-AdministrationRat model of neuropathic painModel of neuropathic painTreatment of benign prostatic hyperplasiaUse disorderPotential of finasterideReduced self-administrationSelf-administration assayWithdrawal-induced hyperalgesiaBenign prostatic hyperplasiaEffects of finasterideSource of therapeutic targetsNeuropathic painOpioid withdrawalInhibitor finasterideSteroidogenesis inhibitorsProstatic hyperplasiaAntinociceptive effectTreatment optionsRat modelFinasterideMultiple opioidsVoiding and Storage Domain-Specific Symptom Score Outcomes After Prostate Artery Embolization for Lower Urinary Tract Symptoms and Urinary Retention
Powell T, Staib L, Liu B, Bhatia S, Chai T, Ayyagari R. Voiding and Storage Domain-Specific Symptom Score Outcomes After Prostate Artery Embolization for Lower Urinary Tract Symptoms and Urinary Retention. Urology 2021, 156: 216-224. PMID: 33961894, DOI: 10.1016/j.urology.2021.02.046.Peer-Reviewed Original ResearchConceptsLower urinary tract symptomsProstate artery embolizationBenign prostatic hyperplasiaUrinary tract symptomsLUTS patientsIPSS-VUrinary retentionRetention patientsArtery embolizationTract symptomsTotal International Prostate Symptom ScoreDomain scoresInternational Prostate Symptom ScoreComponent scoresProstate Symptom ScoreSingle centerSymptom scoresLife scoresProstatic hyperplasiaIPSSPatientsPre-PAEQoLMonthsScore outcomes
2020
Modern best practice in the management of benign prostatic hyperplasia in the elderly
Bortnick E, Brown C, Simma-Chiang V, Kaplan S. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Therapeutic Advances In Urology 2020, 12: 1756287220929486. PMID: 32547642, PMCID: PMC7273551, DOI: 10.1177/1756287220929486.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstatic hyperplasiaManagement of benign prostatic hyperplasiaTreatment of benign prostatic hyperplasiaElderly malesUrinary tract symptomsMinimally invasive techniquesLong-term riskTransurethral resectionMedical therapySurgical optionsEjaculatory functionInvasive techniquesGeneral anesthesiaTreatment planningSide effectsGold standardPatientsProcedural techniquesDebilitating diseaseHyperplasiaEffective alternativeTreatmentMaleUroLift
2019
Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up
Ayyagari R, Powell T, Staib L, Chapiro J, Raja A, Bhatia S, Chai T, Schoenberger S, Devito R. Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up. Journal Of Vascular And Interventional Radiology 2019, 31: 99-107. PMID: 31771896, DOI: 10.1016/j.jvir.2019.08.005.Peer-Reviewed Original ResearchMeSH KeywordsAcrylic ResinsAge FactorsAgedAged, 80 and overComorbidityCone-Beam Computed TomographyConnecticutEmbolization, TherapeuticGelatinHumansLower Urinary Tract SymptomsMaleMiddle AgedOrgan SizeParticle SizeProstateProstatic HyperplasiaQuality of LifeRecovery of FunctionRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsInternational Prostate Symptom ScoreLower urinary tract symptomsPost-void residualCharlson Comorbidity IndexProstatic artery embolizationProstate gland volumeMedian lobe enlargementBenign prostatic hyperplasiaTrisacryl gelatin microspheresArtery embolizationProstatic hyperplasiaGland volumeAdverse event recordingMedical therapy failureClavien-Dindo classificationProstate Symptom ScoreMedium-term followUrinary tract symptomsLower urinary tractMedium-term outcomesPost-procedure valuesQuality of lifeComorbidity indexTract symptomsConsecutive patientsMedical Therapies for Treatment of BPH: Special Considerations in Elderly Men
Bortnick E, Simma-Chiang V, Omidele O, Kaplan S. Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men. Current Geriatrics Reports 2019, 8: 310-314. DOI: 10.1007/s13670-019-00299-1.Peer-Reviewed Original ResearchSurgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019.
Foster H, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary K. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. Journal Of Urology 2019, 202: 592-598. PMID: 31059668, DOI: 10.1097/ju.0000000000000319.Peer-Reviewed Original ResearchConceptsBenign prostatic hyperplasiaLUTS/benign prostatic hyperplasiaLower urinary tract symptomsUrinary tract symptomsTract symptomsSurgical managementProstatic hyperplasiaMale lower urinary tract symptomsEvidence-based surgical managementAssociated treatment algorithmFuture surgical optionsPre-operative testsInvasive surgical therapiesEvidence-based recommendationsQuality of lifeSufficient evidenceHealthcare of patientsLUTS increasesSurgical therapyConditional recommendationSurgical optionsTreatment algorithmCochrane LibraryBody of evidenceImportant diagnosisCase-Control Comparison of Conventional End-Hole versus Balloon-Occlusion Microcatheter Prostatic Artery Embolization for Treatment of Symptomatic Benign Prostatic Hyperplasia
Ayyagari R, Powell T, Staib L, Chapiro J, Schoenberger S, Devito R, Pollak J. Case-Control Comparison of Conventional End-Hole versus Balloon-Occlusion Microcatheter Prostatic Artery Embolization for Treatment of Symptomatic Benign Prostatic Hyperplasia. Journal Of Vascular And Interventional Radiology 2019, 30: 1459-1470. PMID: 31375451, DOI: 10.1016/j.jvir.2019.05.033.Peer-Reviewed Original ResearchConceptsProstatic artery embolizationBenign prostatic hyperplasiaEH groupArtery embolizationSymptomatic improvementAdverse eventsProstatic hyperplasiaInternational Prostate Symptom Score improvementTrial successSymptomatic benign prostatic hyperplasiaBO groupContrast material useProstatic artery anatomySymptom score improvementAdverse event ratesProcedural metricsResidual improvementCase-control comparisonClinical improvementRetrospective reviewArtery anatomyMicrocatheter selectionContrast materialScore improvementEvent ratesComparing Outcomes of Medical Management and Minimally Invasive Surgical Techniques for Lower Urinary Tract Symptoms due to BPH
Sterling J, Farber N, Gupta N. Comparing Outcomes of Medical Management and Minimally Invasive Surgical Techniques for Lower Urinary Tract Symptoms due to BPH. Current Urology Reports 2019, 20: 29. PMID: 30989392, DOI: 10.1007/s11934-019-0896-2.Peer-Reviewed Original ResearchConceptsMinimally invasive surgical therapiesInvasive surgical therapiesMedical therapySurgical therapyUrinary tract symptoms due to benign prostatic hyperplasiaLower urinary tract symptoms due to benign prostatic hyperplasiaSymptoms due to benign prostatic hyperplasiaLower urinary tract symptomsFirst-line management strategyMinimally invasive surgical techniquesUrinary tract symptomsBenign prostatic hyperplasiaOutcome of medical managementOutcomes of medical therapyInvasive surgical techniquesPrescribed medical therapyLUTS/BPH symptomsProstatic hyperplasiaWatchful waitingFirst-lineInvasive therapySurgical techniqueInvasive proceduresCompare outcomesTherapyLong-term Consequences of Medical Therapy for Benign Prostatic Hyperplasia.
Bortnick E, Simma-Chiang V, Kaplan S. Long-term Consequences of Medical Therapy for Benign Prostatic Hyperplasia. Reviews In Urology 2019, 21: 154-157. PMID: 32071563, PMCID: PMC7020283.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaMedical therapyProstatic hyperplasiaTreatment of benign prostatic hyperplasiaUrinary tract symptomsGold standard therapySexual side effectsTransurethral resectionStandard therapySide effectsTherapyLong-term consequencesPatientsHyperplasiaMedicationPotential riskTURPResectionProstateSurgeryLong-term
2015
Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin DT, Nakamura K, Honda M, Inoue K, Saito M. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLOS ONE 2015, 10: e0133798. PMID: 26308715, PMCID: PMC4550428, DOI: 10.1371/journal.pone.0133798.Peer-Reviewed Original ResearchMeSH KeywordsActinsAdrenergic alpha-1 Receptor AntagonistsAnimalsChemokine CXCL1Fibroblast Growth Factor 2IndolesInterleukin-6MaleMalondialdehydeProstateProstatic HyperplasiaRatsRats, Inbred SHRReceptors, Adrenergic, alpha-1Regional Blood FlowTransforming Growth Factor beta1Tumor Necrosis Factor-alphaConceptsProstatic blood flowEffects of silodosinBasic fibroblast growth factorAlpha1A-adrenoceptor antagonistInterleukin-6Blood flowBlood pressureProstatic hyperplasiaHypertensive ratsTissue levelsWKY ratsΑ-SMATGF-β1Twelve-week-old male SHRsVentral prostateCytokine-induced neutrophil chemoattractant-1Selective alpha1A-adrenoceptor antagonistAlpha-smooth muscle actinGrowth factor beta 1Neutrophil chemoattractant-1Spontaneously Hypertensive RatsBenign prostatic enlargementBody weight ratioWistar-Kyoto ratsMorphological abnormalitiesProtective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat
Holmström F, Shimizu S, Shimizu T, Higashi Y, Martin DT, Honda M, Saito M. Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. The Prostate 2015, 75: 1774-1782. PMID: 26286428, DOI: 10.1002/pros.23063.Peer-Reviewed Original ResearchConceptsVentral prostateBlood pressureHypertensive ratsWKY ratsInflammatory cytokinesProstatic hyperplasiaIL-6Growth factorΑ-SMATGF-β1Twelve-week-old SHRMorphological abnormalitiesROCK activityTail-cuff methodBody weight ratioWistar-Kyoto ratsHypertensive rat modelSmooth muscle contractionRho-kinase pathwayWeeks of ageRho-kinase inhibitorSmooth muscle differentiation markersInflammatory markersChronic treatmentProstate weight
2014
Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia
Han LC, Kim SP, Gross CP, Ross JS, Van Houten HK, Smaldone MC, Krambeck AE, Shah ND. Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia. Medical Care 2014, 52: 128-136. PMID: 24423810, DOI: 10.1097/mlr.0000000000000078.Peer-Reviewed Original ResearchConceptsIncident benign prostatic hyperplasiaBenign prostatic hyperplasiaPrimary care providersMedical therapyProstatic hyperplasiaPhysician specialtyNew agentsRespective drug classesAdministrative claims databaseLittle available evidenceRetrospective cohortMedical managementClaims databaseMonths postdiagnosisInsured patientsDrug classesCare providersBlockersReductase inhibitorsPatientsExisting agentsAvailable evidenceUrologistsOverall useHyperplasia
2011
POD-04.06 The Effect of Increasing Doses of a Saw Palmetto Fruit Extract on Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Randomized Trial
Roehrborn C, McVary K, Nickel J, Crawford E, Kreder K, Naslund M, Andriole G, Kaplan S, Foster H, Kusek J. POD-04.06 The Effect of Increasing Doses of a Saw Palmetto Fruit Extract on Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Randomized Trial. Urology 2011, 78: s14. DOI: 10.1016/j.urology.2011.07.427.Peer-Reviewed Original Research
2009
Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity
Mongiu A, McVary K. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Current Prostate Reports 2009, 7: 63-69. DOI: 10.1007/s11918-009-0010-1.Peer-Reviewed Original ResearchLower urinary tract symptomsBenign prostatic hyperplasiaBPH/lower urinary tract symptomsUrinary tract symptomsLifestyle modificationTract symptomsProstatic hyperplasiaGlobal public health challengeParticular polymorphismsCommon neoplastic conditionPrevalence of obesityClinical trial methodologyPublic health challengeStrong independent relationshipProstate sizePhysical inactivityTrial methodologyNeoplastic conditionsEpidemiological studiesObesityHealth challengesIndependent relationshipIndividual treatmentHyperplasiaSymptomsLower urinary tract symptoms, benign prostatic hyperplasia, and obesity
Mongiu AK, McVary KT. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Current Urology Reports 2009, 10: 247-253. PMID: 19570484, DOI: 10.1007/s11934-009-0041-8.Peer-Reviewed Original ResearchConceptsLower urinary tract symptomsBenign prostatic hyperplasiaBPH/lower urinary tract symptomsUrinary tract symptomsLifestyle modificationTract symptomsProstatic hyperplasiaGlobal public health challengeParticular polymorphismsCommon neoplastic conditionPrevalence of obesityClinical trial methodologyPublic health challengeStrong independent relationshipProstate sizePhysical inactivityTrial methodologyNeoplastic conditionsEpidemiological studiesObesityHealth challengesIndependent relationshipIndividual treatmentHyperplasiaSymptomsLack of Immunohistochemical Detection of VEGF in Prostate Carcinoma
Kamath A, Helie M, Bifulco CB, Li WW, Concato J, Jain D. Lack of Immunohistochemical Detection of VEGF in Prostate Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2009, 17: 227-232. PMID: 19098681, DOI: 10.1097/pai.0b013e31818f9e7f.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorVEGF expressionBenign glandsMalignant glandsDifferent antigen retrieval techniquesVeterans Health Administration hospitalsEndothelial cellsBenign prostatic hyperplasiaRenal cell carcinomaDifferent antibodiesNonspecific stainingPotential therapeutic targetEndothelial growth factorCell carcinomaProstatic hyperplasiaAntigen retrieval methodAntigen retrieval techniqueFibromuscular stromaAdministration HospitalBreast carcinomaProstatic adenocarcinomaHepatocellular carcinomaProstate carcinomaStudy populationIHC analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply